JP2018529739A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529739A5
JP2018529739A5 JP2018517345A JP2018517345A JP2018529739A5 JP 2018529739 A5 JP2018529739 A5 JP 2018529739A5 JP 2018517345 A JP2018517345 A JP 2018517345A JP 2018517345 A JP2018517345 A JP 2018517345A JP 2018529739 A5 JP2018529739 A5 JP 2018529739A5
Authority
JP
Japan
Prior art keywords
alkylene
aryl
cycloalkyl
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018517345A
Other languages
English (en)
Japanese (ja)
Other versions
JP6896715B2 (ja
JP2018529739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/054657 external-priority patent/WO2017059191A1/en
Publication of JP2018529739A publication Critical patent/JP2018529739A/ja
Publication of JP2018529739A5 publication Critical patent/JP2018529739A5/ja
Application granted granted Critical
Publication of JP6896715B2 publication Critical patent/JP6896715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018517345A 2015-09-30 2016-09-30 セピアプテリン還元酵素としてのヘテロアリール誘導体 Active JP6896715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235191P 2015-09-30 2015-09-30
US62/235,191 2015-09-30
PCT/US2016/054657 WO2017059191A1 (en) 2015-09-30 2016-09-30 Heteroaryl derivatives as sepiapterin reductase inhibitors

Publications (3)

Publication Number Publication Date
JP2018529739A JP2018529739A (ja) 2018-10-11
JP2018529739A5 true JP2018529739A5 (cg-RX-API-DMAC10.html) 2019-11-14
JP6896715B2 JP6896715B2 (ja) 2021-06-30

Family

ID=57133442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018517345A Active JP6896715B2 (ja) 2015-09-30 2016-09-30 セピアプテリン還元酵素としてのヘテロアリール誘導体

Country Status (7)

Country Link
US (1) US9963462B2 (cg-RX-API-DMAC10.html)
EP (1) EP3356345B1 (cg-RX-API-DMAC10.html)
JP (1) JP6896715B2 (cg-RX-API-DMAC10.html)
CA (1) CA3038280A1 (cg-RX-API-DMAC10.html)
DK (1) DK3356345T3 (cg-RX-API-DMAC10.html)
ES (1) ES2969565T3 (cg-RX-API-DMAC10.html)
WO (1) WO2017059191A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
CN107312011A (zh) * 2017-06-29 2017-11-03 上海药明康德新药开发有限公司 外消旋‑7‑叔丁氧基羰基‑1‑氧亚基‑2,7‑二氮杂螺壬烷‑4‑羧酸的合成方法
CN107817307B (zh) * 2017-11-01 2020-12-25 重庆华邦制药有限公司 Hplc法分离测定帕司烟肼及其相关杂质的方法
EP3743408A1 (en) 2018-01-23 2020-12-02 Basf Se Preparation of optionally substituted dihydroisoquinolines
WO2019145174A1 (en) 2018-01-23 2019-08-01 Basf Se Preparation of optionally substituted 5-substituted pyridine
EP3743407B1 (en) 2018-01-23 2022-08-03 Basf Se Bromination of pyridine derivatives
US11591312B2 (en) 2018-01-23 2023-02-28 Basf Se Halogenation of pyridine derivatives
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
TWI803696B (zh) * 2018-09-14 2023-06-01 日商橘生藥品工業股份有限公司 次黃嘌呤化合物
US11401273B2 (en) 2018-11-20 2022-08-02 Piramal Pharma Limited Asymmetric synthesis of Azaspiro compounds
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20220082804A (ko) * 2019-07-17 2022-06-17 싸이토키네틱스, 인코포레이티드 심장 근섬유분절 억제제 경구 제제들
WO2021077102A1 (en) * 2019-10-18 2021-04-22 The Board Of Regents Of The University Of Texas System Novel antiparasitic compounds and methods
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物
JP2021123539A (ja) * 2020-02-03 2021-08-30 キッセイ薬品工業株式会社 ピロロピリミジノン化合物
US20240092784A1 (en) * 2020-04-14 2024-03-21 Nissan Chemical Corporation Condensed heterocyclic compound
CN111393366B (zh) * 2020-06-05 2020-09-01 北京华氏开元医药科技有限公司 四氢异喹啉类衍生物、制备方法、药物组合物及应用
TW202220967A (zh) * 2020-07-24 2022-06-01 美商伊尼製藥股份有限公司 噻吩hsd17b13抑制劑及其用途
CN114262322B (zh) * 2020-09-16 2026-01-06 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
EP4244210A4 (en) 2020-11-13 2024-10-30 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
CN113072420B (zh) * 2021-02-23 2022-05-20 中山大学 一类2-芳基取代的偕二氟环丁烷类化合物及其制备方法
CN116490498B (zh) * 2021-03-19 2025-09-02 南京迈晟科技有限责任公司 嘧啶并环类化合物及其用于制备治疗疼痛、脊髓损伤药物中的用途
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Kdm5阻害作用を有する化合物を含有する医薬組成物
CN119365460A (zh) 2022-04-08 2025-01-24 尚医治疗有限责任公司 与Ras超家族蛋白相互作用以用于治疗癌症、炎性疾病、RAS病和纤维化疾病的化合物
WO2024109788A1 (zh) * 2022-11-23 2024-05-30 成都先导药物开发股份有限公司 Parp7抑制剂及其制备方法和用途
CN116496195A (zh) * 2023-05-10 2023-07-28 南京优氟医药科技有限公司 一种(r)-4,4-二氟代吡咯烷-2-羧酸的制备方法
WO2025006293A2 (en) * 2023-06-26 2025-01-02 Merck Sharp & Dohme Llc Inhibitors of human respiratory syncytial virus and metapneumovirus

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040047A (en) 1960-04-04 1962-06-19 Takeda Pharmaceutical 2-(pyrazol-1-yl)-pyrimidine derivatives
JPH04182636A (ja) 1990-11-19 1992-06-30 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
JPH05341428A (ja) 1992-06-10 1993-12-24 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
TW312694B (cg-RX-API-DMAC10.html) 1994-09-26 1997-08-11 Daiichi Seiyaku Co
ATE306481T1 (de) 1999-05-12 2005-10-15 Ortho Mcneil Pharm Inc Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
EP1451160B1 (en) * 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
BR0207215A (pt) * 2001-12-13 2004-02-10 Daiichi Suntory Pharma Co Ltd Derivados de pirazolopiriminona tendo ação de inibição de pde7
GB2388594A (en) * 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6933386B2 (en) 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
JP2007511520A (ja) 2003-11-13 2007-05-10 ザ ジェネラル ホスピタル コーポレーション 疼痛を治療するための方法
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
RU2380101C2 (ru) 2004-09-30 2010-01-27 Тиботек Фармасьютикалз Лтд. Бициклические пиримидины, ингибирующие hcv
BRPI0608411A2 (pt) 2005-03-10 2009-12-29 Basf Ag uso de um composto, composto, processo para preparar compostos, agente, semente, e, processo para combater fungos nocivos fitopatogênicos
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
EP1921067A1 (en) 2006-11-08 2008-05-14 Bayer Schering Pharma Aktiengesellschaft Indole and indazole derivatives as anti-inflammatory agents
WO2008055709A1 (en) 2006-11-08 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Indazole and indole derivatives as anti -inflammatory agents
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
DK2134691T3 (da) 2007-03-08 2012-05-07 Janssen Pharmaceutica Nv Quinolinonderivativer som parp- og tank-inhibitorer
WO2008131050A1 (en) 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP2010526793A (ja) 2007-05-10 2010-08-05 グラクソ グループ リミテッド P2x7調節因子としてのピラゾール誘導体
SI2178865T1 (sl) * 2007-07-19 2015-11-30 Lundbeck, H., A/S 5-členski heterociklični amidi in sorodne spojine
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
CN102388037B (zh) * 2009-02-10 2014-12-03 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的喹唑啉酮
WO2011035009A1 (en) * 2009-09-17 2011-03-24 Hercules Technology Management Co V, Inc. Heterocyclic gtp cyclohydrolase 1 inhibitors for the treatment of pain
AU2010306750B2 (en) 2009-10-15 2014-11-13 Children's Medical Center Corporation Sepiapterin reductase inhibitors for the treatment of pain
WO2011088045A1 (en) 2010-01-12 2011-07-21 Ambit Biosciences Corporation Aurora kinase compounds and methods of their use
WO2011138142A1 (en) 2010-05-07 2011-11-10 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions and use of sulfasalazine
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
HRP20161033T1 (hr) 2012-05-04 2016-10-21 Merck Patent Gmbh Derivati pirolotriazinona
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
AR097631A1 (es) * 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos

Similar Documents

Publication Publication Date Title
JP2018529739A5 (cg-RX-API-DMAC10.html)
JP2017511357A5 (cg-RX-API-DMAC10.html)
JP2019502763A5 (cg-RX-API-DMAC10.html)
JP2016515560A5 (cg-RX-API-DMAC10.html)
JP2015514808A5 (cg-RX-API-DMAC10.html)
JP2017509689A5 (cg-RX-API-DMAC10.html)
JP2016514719A5 (cg-RX-API-DMAC10.html)
JP2010526098A5 (cg-RX-API-DMAC10.html)
JP2019512505A5 (cg-RX-API-DMAC10.html)
JP2015537017A5 (cg-RX-API-DMAC10.html)
JP2019524883A5 (cg-RX-API-DMAC10.html)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2018524390A5 (cg-RX-API-DMAC10.html)
JP2018529650A5 (cg-RX-API-DMAC10.html)
JP2015503625A5 (cg-RX-API-DMAC10.html)
JP2016506961A5 (cg-RX-API-DMAC10.html)
JP2012524056A5 (cg-RX-API-DMAC10.html)
JP2016525135A5 (cg-RX-API-DMAC10.html)
AR081830A1 (es) Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos
JP2016540742A5 (cg-RX-API-DMAC10.html)
JP2015531366A5 (cg-RX-API-DMAC10.html)
JP2010522194A5 (cg-RX-API-DMAC10.html)
JP2017517512A5 (cg-RX-API-DMAC10.html)
JP2016523974A5 (cg-RX-API-DMAC10.html)
JP2014510147A5 (cg-RX-API-DMAC10.html)